TY - JOUR
T1 - Bromocriptine
T2 - Problems with low-dose de novo therapy in Parkinson's disease
AU - Grimes, J. D.
AU - Delgado, M. R.
PY - 1985/1/1
Y1 - 1985/1/1
N2 - Twenty Parkinson's disease patients, who had not yet received levodopa, were treated with low-dose bromocriptine. At a mean daily bromocriptine dose of 13.2 mg, 13 patients (65%) improved and had a 32% reduction in the combined score for tremor rigidity and bradykinesia. Adverse effects were frequent, and 25% of the patients were taken off the drug because of nausea or vomiting. After 30 months follow-up, only three patients continued on bromocriptine alone. Ten patients were eventually maintained on low-dose bromocriptine and levodopa-carbidopa, and a clear synergistic effect of bromocriptine in this drug combination was documented in eight patients. Low-dose bromocriptine does not replace levodopa as initial therapy for Parkinson's disease. The potential long-term benefit of the early use of combined low-dose levodopa-dopamine agonist therapy needs to be further studied.
AB - Twenty Parkinson's disease patients, who had not yet received levodopa, were treated with low-dose bromocriptine. At a mean daily bromocriptine dose of 13.2 mg, 13 patients (65%) improved and had a 32% reduction in the combined score for tremor rigidity and bradykinesia. Adverse effects were frequent, and 25% of the patients were taken off the drug because of nausea or vomiting. After 30 months follow-up, only three patients continued on bromocriptine alone. Ten patients were eventually maintained on low-dose bromocriptine and levodopa-carbidopa, and a clear synergistic effect of bromocriptine in this drug combination was documented in eight patients. Low-dose bromocriptine does not replace levodopa as initial therapy for Parkinson's disease. The potential long-term benefit of the early use of combined low-dose levodopa-dopamine agonist therapy needs to be further studied.
UR - http://www.scopus.com/inward/record.url?scp=0021992830&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021992830&partnerID=8YFLogxK
U2 - 10.1097/00002826-198503000-00007
DO - 10.1097/00002826-198503000-00007
M3 - Article
C2 - 3978651
AN - SCOPUS:0021992830
SN - 0362-5664
VL - 8
SP - 73
EP - 77
JO - Clinical Neuropharmacology
JF - Clinical Neuropharmacology
IS - 1
ER -